Molecular/genetic therapies in ovarian cancer: future opportunities and challenges
Ovarian cancer is the most lethal gynecologic cancer. Traditional therapies have included surgical management and cytotoxic chemotherapy; however, treatment paradigms continue to shift from empiric cytotoxic chemotherapy to more individualized treatment. Recent research efforts have focused on deter...
Saved in:
Published in | Clinical obstetrics and gynecology Vol. 55; no. 1; p. 156 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
01.03.2012
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Ovarian cancer is the most lethal gynecologic cancer. Traditional therapies have included surgical management and cytotoxic chemotherapy; however, treatment paradigms continue to shift from empiric cytotoxic chemotherapy to more individualized treatment. Recent research efforts have focused on determining and targeting the molecular biological mechanisms of ovarian cancer in an attempt to develop novel therapeutic modalities with the ultimate goal of improving outcome while limiting toxicity. This chapter reviews progress in the development of novel therapies directed at major pathways implicated in ovarian tumorigenesis including angiogenesis, PARP inhibition, signal transduction, antifolate therapies, death receptor-mediated therapies, histone deacetylase inhibition, immunotherapeutics, and oncolytics. |
---|---|
AbstractList | Ovarian cancer is the most lethal gynecologic cancer. Traditional therapies have included surgical management and cytotoxic chemotherapy; however, treatment paradigms continue to shift from empiric cytotoxic chemotherapy to more individualized treatment. Recent research efforts have focused on determining and targeting the molecular biological mechanisms of ovarian cancer in an attempt to develop novel therapeutic modalities with the ultimate goal of improving outcome while limiting toxicity. This chapter reviews progress in the development of novel therapies directed at major pathways implicated in ovarian tumorigenesis including angiogenesis, PARP inhibition, signal transduction, antifolate therapies, death receptor-mediated therapies, histone deacetylase inhibition, immunotherapeutics, and oncolytics. |
Author | Ziebarth, Angela J Alvarez, Ronald D Landen, Jr, Charles N |
Author_xml | – sequence: 1 givenname: Angela J surname: Ziebarth fullname: Ziebarth, Angela J organization: The Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, Albama 35249, USA – sequence: 2 givenname: Charles N surname: Landen, Jr fullname: Landen, Jr, Charles N – sequence: 3 givenname: Ronald D surname: Alvarez fullname: Alvarez, Ronald D |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22343235$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j91Kw0AQRhdR7I--gci-QNrdmewm650UW4WKUPS6TDaTNpJuwiYRfHsV9eq7ORzONxPnoQ0sxI1WC61cttzs1gtVKI2MOoe00Na5MzHVBiExBtREzPr-XSmdmkxfigkApghopmL33Dbsx4bi8sCBh9rL4ciRupp7WQfZflCsKUhPwXO8k9U4jJFl23VtHMZQDz8chVL6IzUNhwP3V-Kioqbn67-di7f1w-vqMdm-bJ5W99vEo1KYoHb0neGArLec-xIKRAuuKpCtMS7ngm0KKvOqsuTyqixzBkjRgSeGEubi9tfbjcWJy30X6xPFz_3_OfgCkLdTfA |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/GRF.0b013e31824b1699 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-5520 |
ExternalDocumentID | 22343235 |
Genre | Journal Article Review |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 0R~ 1CY 29B 354 3O- 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6J9 6PF 85S AAAAV AAHPQ AAIQE AAQQT AARTV AASCR AASXQ AAWTL AAYJJ ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACILI ACNWC ACOAL ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFFNX AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJIOK AJNWD AJNYG AJZMW ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 BYPQX C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF7 JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI L-C L7B N4W N9A NPM N~M O9- OAG OAH OB2 OBH OCUKA ODA OHH OJAPA OL1 OLB OLG OLV OLW OLZ OPUJH ORVUJ OUVQU OVD OVDNE OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW TWZ V2I VVN W3M WOQ WOW X3V X3W X7M XXN XYM YFH YOC YZZ ZB8 ZFV ZGI ZXP ZY1 ZZMQN |
ID | FETCH-LOGICAL-c3003-319a23492a6c6e8cd2b33629fb3e65598ebe64207c0f6a98fdd8e224392cae2d2 |
IngestDate | Sat Sep 28 08:03:35 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3003-319a23492a6c6e8cd2b33629fb3e65598ebe64207c0f6a98fdd8e224392cae2d2 |
PMID | 22343235 |
ParticipantIDs | pubmed_primary_22343235 |
PublicationCentury | 2000 |
PublicationDate | 2012-March |
PublicationDateYYYYMMDD | 2012-03-01 |
PublicationDate_xml | – month: 03 year: 2012 text: 2012-March |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical obstetrics and gynecology |
PublicationTitleAlternate | Clin Obstet Gynecol |
PublicationYear | 2012 |
SSID | ssj0014571 |
Score | 2.1107042 |
SecondaryResourceType | review_article |
Snippet | Ovarian cancer is the most lethal gynecologic cancer. Traditional therapies have included surgical management and cytotoxic chemotherapy; however, treatment... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 156 |
SubjectTerms | Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Bevacizumab CA-125 Antigen Clinical Trials as Topic Enzyme Inhibitors - therapeutic use Female Folate Receptor 1 - antagonists & inhibitors Genes, BRCA1 Genes, BRCA2 Genetic Therapy Histone Deacetylase Inhibitors - therapeutic use Humans Insulin-Like Growth Factor Binding Protein 1 - antagonists & inhibitors Interleukin-12 - therapeutic use Mutation Oncogene Protein v-akt - antagonists & inhibitors Ovarian Neoplasms - blood supply Ovarian Neoplasms - drug therapy Poly(ADP-ribose) Polymerase Inhibitors Protein Kinase Inhibitors - therapeutic use Receptors, TNF-Related Apoptosis-Inducing Ligand - antagonists & inhibitors Sirolimus - analogs & derivatives Sirolimus - therapeutic use Taxoids - therapeutic use Vascular Endothelial Growth Factor A - antagonists & inhibitors |
Title | Molecular/genetic therapies in ovarian cancer: future opportunities and challenges |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22343235 |
Volume | 55 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF5aBfEivt-yB28lmiabl7dSrEVsD6WF4kWym40Walq0Cnrznzub2TRpraJeQsmmS8h8u8zMzvcNIae-wyTjPDRiRwqDhaoIQAppmH7sKf3vqMoU37nVdps9dt13-qXSR5FdMuFn4n0hr-Q_VoV7YFfFkv2DZaeTwg34DfaFK1gYrr-ycSvrbQtTwEOKj1hBQtUgrbOqjF4hFIYVLJRt04aQqCFSGY2V3_2SpHqqyG3Luqo8F_3VekacHHGAg1Lzx6fv3xIpZjLytwOpigMesEryXg7D_MTpRmWqkQTyVDjjz4-BakN4Ucxld9JktS5E1ukIVdeR1WOdyWwLhfDWscziHotSvDNYwg2zirLiXzZyFAi-6jTyTK3FeNXFbkoF244fU-OCl8NsC5VPfh6dk9fOhsqk7Plqi2yrdI8-hmKOV834loF3vuh1lJq0nmIuMkk9lO46WdOhBa0hTjZISSabZKWliye2SGcKl3MNFjoFCx0kVIOFIlguKEKFzkCFgiVpDpVt0mtcdutNQ7fUMIRtpkzKILSUIGXoClf6IrK4DS5MEHNbukqrH9Y0RKSmJ8zYDQM_jiJfgpcHXrQIpRVZO2QpGSVyj1DfDr3AdCMB_2QytgLGYxEJCKdN1wene5_s4te4G6Nuyl32nQ6-HTkkqzmmjshyDAtVHoPXN-EnqWU-AeM_V_k |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular%2Fgenetic+therapies+in+ovarian+cancer%3A+future+opportunities+and+challenges&rft.jtitle=Clinical+obstetrics+and+gynecology&rft.au=Ziebarth%2C+Angela+J&rft.au=Landen%2C+Jr%2C+Charles+N&rft.au=Alvarez%2C+Ronald+D&rft.date=2012-03-01&rft.eissn=1532-5520&rft.volume=55&rft.issue=1&rft.spage=156&rft_id=info:doi/10.1097%2FGRF.0b013e31824b1699&rft_id=info%3Apmid%2F22343235&rft_id=info%3Apmid%2F22343235&rft.externalDocID=22343235 |